Global Hospital Acquired Infections Diagnostics Market Revenue Grows at a CAGR of 1.55% .

Introduction

Straits Research released its highly anticipated report, “Global Hospital Acquired Infections Diagnostics Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 4.16 billion in 2025 and is anticipated to grow till USD 4.76 billion by 2034, growing at a CAGR of 1.55% from 2026-2034.

Market Dynamics

The hospital acquired infections diagnostics market continues to expand as healthcare systems strengthen their focus on early pathogen identification, prevention strategies, and improved clinical decision pathways. A key driver for market growth is the rising incorporation of structured infection control programs within hospitals that rely on timely diagnostic insights to detect organisms associated with urinary tract infections, pneumonia, surgical site infections, and bloodstream infections. As patient volumes increase and healthcare facilities adopt more standardized surveillance practices, laboratories seek diagnostic platforms that support rapid turnaround times, consistent organism detection, and alignment with antimicrobial stewardship protocols. This growing emphasis on diagnostic precision enhances demand for both molecular and conventional testing tools across clinical settings.

A central restraint affecting market progression is the variation in specimen quality resulting from inconsistencies in collection methods, storage conditions, or transport timelines. Such variability impacts culture growth, molecular assay sensitivity, and contamination rates, leading to repeated testing cycles and delays in diagnostic interpretation. These inconsistencies challenge laboratory efficiency and create workflow disruptions in environments that require dependable diagnostic output to manage infection risk.

An emerging opportunity lies in the expansion of collaborative hospital networks developing unified diagnostic stewardship models. These networks aim to streamline testing protocols, improve data integration across departments, and strengthen pathogen surveillance through coordinated diagnostic strategies. As institutions align on shared standards for test utilization, reporting formats, and technology adoption, the market benefits from wider deployment of compatible diagnostic platforms. Such initiatives not only enhance infection monitoring capabilities but also open pathways for broader adoption of advanced diagnostic systems across interconnected hospital environments.

Market Highlights

• Test: Based on test, the Molecular segment is anticipated to register the fastest CAGR of 2.12% during the forecast period.
• Infection Type: Based on infection type, the UTI segment dominated the market with 27.12% in 2025.
• Product: Based on product, the Instruments segment is anticipated to register the fastest CAGR of 2.67% during the forecast period.
• Type: By type, the Urinalysis segment is anticipated to register the fastest CAGR of 2.78% during the forecast period.
• Regional Insights: Europe held a dominant share of the global market, accounting for 35.84% in 2025.

Competitive Players

1. Hoffmann-La Roche Ltd
2. Danaher
3. BIOMÉRIEUX
4. Thermo Fisher Scientific Inc
5. BD
6. QIAGEN
7. Bio-Rad Laboratories, Inc.
8. Hologic, Inc.
9. QuidelOrtho Corporation
10. Meridian Bioscience
11. Seegene Inc. 
12. Ecolab Inc.
13. Others

Recent Developments

November 2024: QIAGEN announced the establishment of a new facility in Esplugues de Llobregat, Barcelona, to enhance its QIAstat-Dx operations. The site focused on infectious disease testing and precision medicine, supporting partnerships with Eli Lilly and AstraZeneca.

Segmentation

1. By Test (2026-2034)
   1. Molecular
   2. Conventional
2. By Infection Type (2026-2034)
   1. UTI
   2. Pneumonia
   3. Surgical site infection
   4. Bloodstream infections
   5. Others
3. By Product (2026-2034)
   1. Consumables
   2. Instruments
4. By Type (2026-2034)
   1. Blood tests
   2. Urinalysis